PROGRAM PARTNERSHIPS
Kalypsys is interested in partnerships to advance the following compounds to late stage trials and commercialization:
PPAR delta [KD3010]
KD3010 is an orally administered PPARδ specific agonist. KD3010 is Phase II ready with potential in Diabetes Mellitus and Non-Alcoholic Steatohepatitis (NASH).
GPR119
Kalypsys has proprietary GPR119 selective agonists that demonstrate antidiabetic activity in late stage optimization.
FOR MORE INFORMATION CONTACT:
KALYPSYS SYSTEMS
Wako Pure Chemicals Ltd completed the purchase of the Kalypsys Systems business unit from Kalypsys Inc. on June 24, 2010. Wako is proud to include all of Kalypsys Systems products, known for their unmatched reliability, in its catalog of automated laboratory equipment.
Wako's Automation division sells a wide range of automated laboratory instruments that include fully integrated laboratory robotics systems, compound storage systems, liquid handlers, and more. Kalypsys Systems products will now be sold as Wako's KL product line.
FOR MORE INFORMATION CONTACT:
- Paul Queeney
- pqueeney@wakousa.com
- Rob Bukar
- rbukar@wakousa.com
OR VISIT:
